Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer.

被引：0

作者：

Saunders, Mark P.

Lang, Istvan

Marcuello, Eugenio

Lorusso, Vito

Ocvirk, Janja

Shin, Dongbok

Jonker, Derek J.

Osborne, Stuart

Loeffler, Markus

Waterkamp, Daniel

Cunningham, David

机构：

[1] Christie Hosp NHS Fdn Trust, Withington, England

[2] Natl Inst Oncol, Budapest, Hungary

[3] Hosp St Pau Barcelona, Barcelona, Spain

[4] Vito Fazzi Hosp, Inst Oncol, Bari, Italy

[5] Inst Oncol Ljubljana, Ljubljana, Slovenia

[6] Gachon Univ, Gil Hosp, Dept Internal Med, Inchon, South Korea

[7] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada

[8] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[9] Royal Marsden Hosp NHS Fdn Trust, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3521

引用

页数：1

共 50 条

[21] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
Cabebe, Elwyn C.
Fisher, George A.
Sikic, Branimir I.
INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1082 - 1087
[22] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
Elwyn C. Cabebe
George A. Fisher
Branimir I. Sikic
Investigational New Drugs, 2012, 30 : 1082 - 1087
[23] Predictors of outcome in elderly patients with metastatic colorectal cancer: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment
Omrcen, Tomislav
Katic, Andrija
Tomic, Snjezana
Eterovic, Davor
Vrdoljak, Eduard
ANTI-CANCER DRUGS, 2020, 31 (05) : 518 - 522
[24] Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma
Feliu, J.
Safont, M.
Salud, A.
Losa, F.
Garcia-Giron, C.
Bosch, C.
Escudero, P.
Lopez, R.
Madronal, C.
Gonzalez-Baron, M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[25] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
Hochster, Howard S.
SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
[26] BEVACIZUMAB IN COMBINATION WITH IRINOTECANAND CAPECITABINE AS FIRST-LINE TREATMENT FOR MCRC - EFFICACY AND SAFETY
Sasa, Jungic
Gordana, Kecman Malcic
Ivanka, Rakita
Dusan, Jovanovic
Radoslav, Gajanin
Zdravko, Maric
Biljana, Tubic
Zdenka, Gojkovic
ANNALS OF ONCOLOGY, 2014, 25
[27] A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer
Lueck, Hans-Joachim
Luebbe, Kristina
Bischoff, Joachim
Maass, Nicolai
Feisel, Gabriele
Tome, Oliver
Janni, Wolfgang
Aydogdu, Mustafa
Neuhoeffer, Tanja
Ober, Angelika
Aktas, Bahriye
Park-Simon, Tjoung-Won
Schumacher, Claudia
Hoeffkes, Heinz-Gert
Illmer, Thomas
Wagner, Harald
Mehta, Keyur
Nekljudova, Valentina
Loibl, Sibylle
Von Minckwitz, Gunter
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[28] Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
Bazarbashi, Shouki
Aljubran, Ali
Alzahrani, Ahmad
Mohieldin, Ahmed
Soudy, Hussein
Shoukri, Mohammed
CANCER MEDICINE, 2015, 4 (10): : 1505 - 1513
[29] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
Ubago, R.
Castillo, M. A.
Flores, S.
Beltran, C.
VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
[30] A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
Cartwright, TH
Lopez, T
Vukelja, SJ
Encarnacion, C
Boehm, KA
Asmar, L
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 284S - 284S

← 1 2 3 4 5 →